Literature DB >> 16552750

Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation.

Suzanne Hermeling1, Huub Schellekens, Coen Maas, Martijn F B G Gebbink, Daan J A Crommelin, Wim Jiskoot.   

Abstract

The aim of this study was to determine the sensitivity of transgenic immune tolerant mice for the type and level of aggregation of recombinant human interferon alpha2b (rhIFNalpha2b). RhIFNalpha2b was aggregated by metal-catalyzed oxidation or by incubation at elevated temperature and various pHs. Native rhIFNalpha2b was mixed with oxidized rhIFNalpha2b at different ratios to obtain samples with different aggregation levels. The preparations were characterized by UV and fluorescence spectroscopy, gel permeation chromatography (GPC), dynamic light scattering (DLS), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting, and ELISA. The immunogenicity was evaluated in wild-type mice and transgenic mice immune tolerant for hIFNalpha2. Sera were analyzed by ELISA for the presence of rhIFNalpha2b-specific antibodies. The oxidized and aged preparations widely differed regarding the level and nature of aggregates. All preparations containing aggregates increased the immune response in the wild-type mice as compared to native rhIFNalpha2b and were able to break the tolerance of the transgenic mice. The more native-like the conformation of the aggregated proteins, the more immunogenic the preparations were in the transgenic mice. The native-like aggregates prepared via metal catalysis induced a dose-dependent loss of tolerance in the transgenic mice. In conclusion, the transgenic mouse model can be used to screen rhIFNalpha2b formulations for low levels of immunogenic aggregates obtained under accelerated storage conditions. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552750     DOI: 10.1002/jps.20599

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  57 in total

1.  Structure and function of purified monoclonal antibody dimers induced by different stress conditions.

Authors:  Rajsekhar Paul; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Hermann Beck; Alexandre Briguet; Volker Schnaible; Thomas Buckel; Sabine Boeckle
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

2.  A multi-tiered analytical approach for the analysis and quantitation of high-molecular-weight aggregates in a recombinant therapeutic glycoprotein.

Authors:  Heather Hughes; Charles Morgan; Elizabeth Brunyak; Kristen Barranco; Emily Cohen; Tim Edmunds; Karen Lee
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

Review 3.  Protein particulate detection issues in biotherapeutics development--current status.

Authors:  Tapan K Das
Journal:  AAPS PharmSciTech       Date:  2012-05-08       Impact factor: 3.246

4.  In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.

Authors:  Vasco Filipe; Ivo Que; John F Carpenter; Clemens Löwik; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

5.  How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?

Authors:  Liem Andhyk Halim; Vera Brinks; Wim Jiskoot; Stefan Romeijn; Kearkiat Praditpornsilpa; Anunchai Assawamakin; Huub Schellekens
Journal:  Pharm Res       Date:  2013-11-21       Impact factor: 4.200

6.  Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.

Authors:  Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

7.  Influence of aggregation and route of injection on the biodistribution of mouse serum albumin.

Authors:  Grzegorz Kijanka; Malgorzata Prokopowicz; Huub Schellekens; Vera Brinks
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

8.  Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.

Authors:  Jayant Arora; Yue Hu; Reza Esfandiary; Hasige A Sathish; Steven M Bishop; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; David D Weis
Journal:  MAbs       Date:  2016-08-25       Impact factor: 5.857

9.  Influence of the valine zipper region on the structure and aggregation of the basic leucine zipper (bZIP) domain of activating transcription factor 5 (ATF5).

Authors:  Natalie A Ciaccio; T Steele Reynolds; C Russell Middaugh; Jennifer S Laurence
Journal:  Mol Pharm       Date:  2012-10-23       Impact factor: 4.939

10.  Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice.

Authors:  Kathleen A Stringer; Meghan Tobias; John S Dunn; Jackie Campos; Zachary Van Rheen; Mitra Mosharraf; Rajiv Nayar
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-07-29       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.